Skip to main content

Enzymes Clinical Prior Authorization Criteria Revisions Effective June 30, 2021

Last updated on 5/7/2021

The Texas Health and Human Services Commission (HHSC) will revise the clinical prior authorization criteria guides for enzymes on June 30, 2021, in accordance with the recent U.S. Food and Drug Administration changes. HHSC will revise the references for these documents accordingly. The criteria revisions include the following:

  • Adagen
    • HHSC will remove Adagen due to product discontinuation.
  • Ceprotin
    • HHSC will remove the Ceprotin 400-600 units vial because it is not covered through the outpatient pharmacy benefit.
  • Fabrazyme
    • HHSC will update the age requirement to cover clients who are 2 years of age and older.
  • Revcovi
    • HHSC will add the diagnosis of adenosine deaminase severe combined immunodeficiency disease (ADA-SCID) for Revcovi.

The Enzyme clinical prior authorization is optional for MCOs. The Pharmacy Clinical Prior Authorization Assistance Chart shows the prior authorization each MCO uses and how those authorizations relate to those used for processing fee-for-service Medicaid claims. This chart is updated quarterly. Providers can also refer to the MCO Resources for links to each MCO’s list of clinical prior authorizations.

Email questions or comments to